, Volume 19, Issue 8, pp 795–802 | Cite as

Pharmacoeconomic Fellowships

The Need for Outcome Measures
  • Vittorio Maio
  • Tammy K. Girts
  • Jennifer H. Lofland
  • David B. Nash
Leading Article


Pharmacoeconomic fellowship programmes have been in existence for more than 10 years, but their effectiveness has not been evaluated. The aim of this project was to construct a framework to examine the potential outcome measures for pharmacoeconomic fellowships so that the effectiveness of these programmes may be determined. Using the Donabedian model, the structures, processes, and outcomes of pharmacoeconomic fellowship programmes were investigated. The structures of these programmes include the facilities, qualifications of the teaching staff and organisation, and operations of the institution. Most pharmacoeconomic fellowships are based in academic institutions and the pharmaceutical industry. Credentials of the preceptors and teaching staff consist of an advanced degree and relevant expertise in pharmacoeconomics and outcomes research. The processes of pharmacoeconomic fellowships include the duration of the programme as well as the research skills and the educational components taught. However, current guidelines do not define outcome measures for these pharmacoeconomic fellowships. Potential outcomes may include whether or not a degree was obtained, the management and research skills acquired, as well as the type of experiential training received. Further research is required to develop these outcome measures, so the effectiveness of pharmacoeconomic fellowship programmes may be assessed.


Fellowship Programme Research Skill Advanced Degree Educational Component Pharmacoeconomic Research 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We greatly appreciate the assistance of the following people: Lisa E. Paddock, MPH; Jennifer Koenig, MS; Anne Mooney.


  1. 1.
    Pritchard C. Trends in economic evaluation: OHE briefing No. 36. London, England. Office of Health Economics, 1998Google Scholar
  2. 2.
    Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin Ther 1998; 20 (6): 1194–202PubMedCrossRefGoogle Scholar
  3. 3.
    St. Jean AD, Landis NT. The pharmacoeconomist: an emerging specialist in health care institutions. Am J Hosp Pharm 1993; 50: 1062–9PubMedGoogle Scholar
  4. 4.
    Motheral BR, Grizzle AJ, Armstrong EP, et al. Role of pharmacoeconomics on drug benefit decision-making: results of a survey. Formulary May 2000; 35: 412–21Google Scholar
  5. 5.
    Knapp KK, Blalock SJ, O’Malley CH. ASHP survey of ambulatory care responsibilities of pharmacists in managed care and integrated health systems 1999. Am J Health Syst Pharm 1999; 56 (23): 2431–43PubMedGoogle Scholar
  6. 6.
    Draugalis JR, Coons SJ. The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report. Clin Ther 1994; 16 (3): 523–37PubMedGoogle Scholar
  7. 7.
    Gregor KJ, Draugalis JR. Graduate pharmacoeconomic education and training programs in US colleges of pharmacy. Am J Pharm Educ 1994; 58: 378–81Google Scholar
  8. 8.
    Cooke J, Godman B, Giles-Burness D. Pharmacoeconomics teaching in the North West Region. Pharm J 1994; 252: 864–6Google Scholar
  9. 9.
    Lee J, Lawrence BJ, Sullivan SD, et al. Guidelines for pharmacoeconomic research fellowship. Pharmacotherapy 1999; 19 (9): 1105–9CrossRefGoogle Scholar
  10. 10.
    International Society for Pharmacoeconomics and Outcomes Research. ISPOR directory of fellowships in pharmacoeconomics, health economics, outcomes research or related field of study. Available from: URL: [Accessed 2000 Jul 10]Google Scholar
  11. 11.
    American College of Clinical Pharmacy, editor. Directory of Residencies and Fellowships 2000. Kansas City, (MO): American College of Clinical Pharmacy, 2000Google Scholar
  12. 12.
    American Society of Health-System Pharmacists. Definitions of pharmacy residencies and fellowships. Am J Hosp Pharm 1987; 44: 1142–4Google Scholar
  13. 13.
    Udvarhelyi IS, Colditz GA, Rai A, et al. Cost effectiveness and cost benefit analyses in the medical literature. Ann Intern Med 1992; 116: 238–44PubMedGoogle Scholar
  14. 14.
    Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116–21PubMedCrossRefGoogle Scholar
  15. 15.
    Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. Pharmacoeconomics 2000; 18 (1): 55–62PubMedCrossRefGoogle Scholar
  16. 16.
    Lee JT, Sanchez LA. Interpretation of ‘cost-effective’ and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2622–7PubMedGoogle Scholar
  17. 17.
    Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–5PubMedCrossRefGoogle Scholar
  18. 18.
    Drummond R, Harold SL. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 2000; 283 (16): 2158–60CrossRefGoogle Scholar
  19. 19.
    Marwick C. Pharmacoeconomics: is a drug worth its cost? JAMA 1994; 272 (18): 1395PubMedCrossRefGoogle Scholar
  20. 20.
    Krimsky S. Conflict of interest and cost-effectiveness analysis. JAMA 1999; 282 (15): 1474–5PubMedCrossRefGoogle Scholar
  21. 21.
    Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44 (3): 166–206PubMedCrossRefGoogle Scholar
  22. 22.
    Academy of Managed Care Pharmacy. AMCP reports: managed care pharmacy residency and fellowship programs. Available from: URL: [Accessed 2000 Jul 12]Google Scholar
  23. 23.
    Drug Information Association. Internships in industry. Available from URL: [Accessed 2000 Jul 12]Google Scholar
  24. 24.
    Pharmacoeconomic and Outcomes Research Fellowship Standards. The Office of Health Policy and Clinical Outcomes, Thomas Jefferson University. Jun 2000: 8 (Data on file)Google Scholar
  25. 25.
    Standards for fellowship training in pharmacoeconomics and outcomes research. ISPOR position statement. May 1998: 6 (Data on file)Google Scholar
  26. 26.
    What do you consider an ideal training for the practitioner of pharmacoeconomi c research? ISPOR News Jan–Feb 1999; 5 (1): 4–6. Available from: URL: [Accessed 2000 Jul 12]
  27. 27.
    International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomics: identifying the issues. Advisory Panel Reports; issue 1: 5. Available from: URL: [Accessed 2000 Jul 7]Google Scholar
  28. 28.
    Center for Evaluation of Medicines. Workshops calendar: designing and implementing economic evaluation of medicines. Available from: URL: [Accessed 2000 Jul 12]Google Scholar
  29. 29.
    Harvard School of Public Health. Calendar of events: cost-effective analysis for medical technologies and pharmaceuticals. Available from: URL: [Accessed 2000 Jul 12]Google Scholar
  30. 30.
    Lloyd KB, Lee JT, Strassels S. The relative effects of fellowship training on career path, job satisfaction and burnout, and quality of life. Pharmacotherapy 1998; 28: 430Google Scholar
  31. 31.
    Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Committee on Quality of Healthcare in America, Institute of Medicine. Washington DC: National Academy Press, 2000Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Vittorio Maio
    • 1
  • Tammy K. Girts
    • 1
  • Jennifer H. Lofland
    • 1
  • David B. Nash
    • 1
  1. 1.Office of Health Policy and Clinical OutcomesThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations